{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:36:47Z","timestamp":1791099407481,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Osteoporosis treatments reduce fracture risk but cannot fully eliminate it, and the concept of treatment failure (TF) or inadequate clinical response (ICR) remains debated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aims<\/jats:title>\n            <jats:p>The TAILOR study aims to assess the prevalence of ICR and TF in osteoporotic women undergoing active drug treatment for postmenopausal osteoporosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>TAILOR is a retrospective study conducted in an Italian outpatient service. We included 415 patients with at least 12\u00a0months of treatment and up to 10\u00a0years, examining clinical characteristics predicting TF and ICR. TF was defined as the occurrence of two fragility fractures while on treatment or one fracture plus lack of variation BMD and ICR as the occurrence of a new osteoporotic fracture in treated patients according to previous literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seventy-two patients experienced fractures during the follow-up, of those, 26 (36%) were classified as TF. The clinical characteristics of patients with fractures were similar to those without, except for a longer postmenopausal period and lower lumbar spine bone mineral density (BMD). Postmenopausal period was significantly longer in TF compared to ICR patients. However, no significant differences were found in baseline fractures, prescribed treatments, or fracture-free survival curves with age, postmenopausal period, BMD, and previous treatments. The clinical follow-up was longer in ICR and TF patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>TAILOR shows a higher prevalence of ICR and TF (17.3%) compared to randomized controlled trials and real-world data, with 36% of fractures during follow-up classified as TF. Clinician decisions often led to changes in antiosteoporosis treatment, particularly in TF cases, though TF diagnosis was rarely cited explicitly in medical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>TAILOR emphasizes that common clinical factors do not reliably predict ICR and TF. The findings highlight the complexity of determining an algorithm for the best treatment approach to prevent TF and ICR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40520-025-02972-2","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:55:07Z","timestamp":1740833707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment failure in osteoporosis: who will experience a new Fracture? TAILOR a retrospective study"],"prefix":"10.1007","volume":"37","author":[{"given":"Ilaria","family":"Buondonno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-8337","authenticated-orcid":false,"given":"Patrizia","family":"D\u2019Amelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"2972_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11657-021-00969-8","volume":"17","author":"C Willers","year":"2022","unstructured":"Willers C, Norton N, Harvey NC et al (2022) Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos 17:23. https:\/\/doi.org\/10.1007\/s11657-021-00969-8","journal-title":"Arch Osteoporos"},{"key":"2972_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11657-023-01229-7","volume":"18","author":"A Singer","year":"2023","unstructured":"Singer A, McClung MR, Tran O et al (2023) Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis. Arch Osteoporos 18:42. https:\/\/doi.org\/10.1007\/s11657-023-01229-7","journal-title":"Arch Osteoporos"},{"key":"2972_CR3","first-page":"24","volume":"19","author":"M Barbagallo","year":"2007","unstructured":"Barbagallo M, Dominguez LJ, Maugeri D et al (2007) Quality of life in osteoporotic women with inadequate clinical response to antiresorptive drugs: results from the ICARO study. Aging Clin Exp Res 19:24\u201327","journal-title":"Aging Clin Exp Res"},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/qjmed\/hcl073","volume":"99","author":"F Jakob","year":"2006","unstructured":"Jakob F, Mar\u00edn F, Mart\u00edn-Mola E et al (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 99:531\u2013543. https:\/\/doi.org\/10.1093\/qjmed\/hcl073","journal-title":"QJM"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bone.2010.12.021","volume":"48","author":"X Song","year":"2011","unstructured":"Song X, Shi N, Badamgarav E et al (2011) Cost burden of second fracture in the US health system. Bone 48:828\u2013836. https:\/\/doi.org\/10.1016\/j.bone.2010.12.021","journal-title":"Bone"},{"key":"2972_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00198-010-1223-4","volume":"21","author":"J-J Body","year":"2010","unstructured":"Body J-J, Bergmann P, Boonen S et al (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 21:1657\u20131680. https:\/\/doi.org\/10.1007\/s00198-010-1223-4","journal-title":"Osteoporos Int"},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197\u2013213. https:\/\/doi.org\/10.7326\/0003-4819-148-3-200802050-00198","journal-title":"Ann Intern Med"},{"key":"2972_CR8","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769\u20132774. https:\/\/doi.org\/10.1007\/s00198-012-2093-8","journal-title":"Osteoporos Int"},{"key":"2972_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1359\/jbmr.060715","volume":"21","author":"S Adami","year":"2006","unstructured":"Adami S, Isaia G, Luisetto G et al (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565\u20131570. https:\/\/doi.org\/10.1359\/jbmr.060715","journal-title":"J Bone Miner Res"},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Res Group Lancet 348:1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Fracture Intervention Trial Res Group Lancet"},{"key":"2972_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352. https:\/\/doi.org\/10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391. https:\/\/doi.org\/10.1007\/s001980050010","journal-title":"Osteoporos Int"},{"key":"2972_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645. https:\/\/doi.org\/10.1001\/jama.282.7.637","journal-title":"JAMA"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"2972_CR15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082. https:\/\/doi.org\/10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"2972_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"2972_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00198-008-0566-6","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, Isaia G, Luisetto G et al (2008) Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 19:1219\u20131223. https:\/\/doi.org\/10.1007\/s00198-008-0566-6","journal-title":"Osteoporos Int"},{"key":"2972_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161435.GL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N et al (2016) American Association Of Clinical Endocrinologists And American College Of Endocrinology Clinical Practice Guidelines For The Diagnosis And Treatment Of Postmenopausal Osteoporosis - 2016. Endocr Pract 22:1\u201342. https:\/\/doi.org\/10.4158\/EP161435.GL","journal-title":"Endocr Pract"},{"key":"2972_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","volume":"68","author":"M Rossini","year":"2016","unstructured":"Rossini M, Adami S, Bertoldo F et al (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1\u201339. https:\/\/doi.org\/10.4081\/reumatismo.2016.870","journal-title":"Reumatismo"},{"key":"2972_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00198-008-0659-2","volume":"19","author":"A D\u00edez-P\u00e9rez","year":"2008","unstructured":"D\u00edez-P\u00e9rez A, Gonz\u00e1lez-Mac\u00edas J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 19:1511\u20131516. https:\/\/doi.org\/10.1007\/s00198-008-0659-2","journal-title":"Osteoporos Int"},{"key":"2972_CR21","first-page":"477","volume":"29","author":"S Adami","year":"2011","unstructured":"Adami S, Maugeri D, Toscano V et al (2011) Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO). Clin Exp Rheumatol 29:477\u2013484","journal-title":"Clin Exp Rheumatol"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-02972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-02972-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-02972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:55:10Z","timestamp":1740833710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-02972-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-02972-2","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ilaria Buondonno, Marco Di Stefano and Patrizia D\u2019Amelio declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethical committee \u201cAOU Citt\u00e0 della Salute e della Scienza di Torino - AO. Ordine Mauriziano di Torino \u2013 ASL. Citt\u00e0 di Torino\u201d approved the study protocol (approval number 00418\/2020, date 01.10.2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"No formal consent is required for this kind of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"65"}}